Engitix Therapeutics



To create a healthier future for patients with life-threatening diseases, Engitix Therapeutics is using its pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumors.

Giuseppe Mazza
CEO & Co-Founder
Giuseppe Mazza
David Dally
Chief Financial Officer
Stephen Brindle
Chief Operating Officer
Mike Burbridge
VP, Oncology & Immuno-Oncology

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.